Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. AMD
4. INFY
5. RNG
6. UNP
7. DGX
8. ACI
9. URI
10. ARGX

Go back to Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
AGENUS (NASDAQ: AGEN) Delayed: 6.19 --0 (-0%)
Previous Close $6.19    52 Week High $7.49 
Open $6.19    52 Week Low $2.61 
Day High $6.19    P/E N/A 
Day Low $6.19    EPS $-1.10 
Volume 26,548